- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03420118
Study of Biomarkers in Gynecological Cancers
Molecular and Immunological Characterization of Gynecological Malignancies
In recent years, there has been a significant improvement in understanding the biology of cancer and this information has been used to improve cancer care and patient outcome.
Research has shown that changes in some genes and/or proteins may be important indicators for certain cancers and response to treatments. Genes are molecules made up of ribonucleic acid (RNA) and deoxyribonucleic acid (DNA). DNA contain instructions for the development and functioning of the cells in the body and are passed down from parent to child. RNA is involved with producing proteins in the body. Further research is needed to better understand the changes found in cancer cells and how to target them to stop or reduce cancer growth.
A drug that may be able to block certain specific cancer cell changes is called "targeted therapy". Different people with the same type of cancer receiving the same drug could have different responses to it. For example, one person may experience a reduction of their tumor while another person's cancer may worsen. The reason for this is still not well understood and could lie in gene changes.
Understanding these changes may allow researchers to predict how treatments may work in guiding decisions around choice of drugs.
The purpose of the study is to learn more about gene changes or protein expression (levels) of tumors to better understand the behavior of gynecological diseases and, if possible, better address participants' cancer care now or in the future.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Amit Oza, M.D.
- Phone Number: 416-946-2818
- Email: amit.oza@uhn.ca
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 1Z5
- Recruiting
- Princess Margaret Cancer Centre
-
Contact:
- Amit Oza, M.D.
- Phone Number: 416-946-2818
- Email: amit.oza@uhn.ca
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Pre-Screening Eligibility:
Inclusion Criteria:
- Patients with probable diagnoses of gynecological malignancy (ovarian, tubal, primary peritoneal, uterine, cervical, vulvar and rare gynecological cancers) and confirmed to be undergoing upfront debulking surgery/radiation
- Patient must be ≥16 years of age at the time of consent.
- Ability to understand and provide written informed consent.
- ECOG Performance Status ≤ 2.
- Patient must consent to provide tissue sample from surgery and blood samples
- Life expectancy ≥3 months.
Exclusion Criteria:
- Patients must be treatment naïve (no previous treatment of Neoadjuvant chemotherapy nor radiation for newly diagnosed disease)
Eligibility for Patients with Gynecological Diagnosis
Inclusion Criteria:
- Patients with histological confirmation of gynecological malignancy (except ovarian cancer with high grade serous histology, tubal, primary peritoneal, uterine, cervical, vulvar and vaginal cancer and rare gynecological cancers).
- Patient must be ≥16 years of age at the time of consent.
- Ability to understand and provide written informed consent.
- Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2.
- Patient must consent to providing archival tissue and/or to undergo tumour biopsy and/or to provide blood or fluid collection samples. Patients will also be asked to provide a blood sample for germline mutation analysis.
- Life expectancy ≥3 months.
- No limits of previous lines of treatment.
Exclusion Criteria:
- Any contraindication to tumour biopsy or blood collection
- Patient with diagnosis of High grade serous Ovarian Cancer are excluded
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Tumor tissue and blood samples collection
|
Depending on the status of disease when participants join the study, a sample of tumour tissue may be collected from:
In addition:
Blood samples will be collected at the following different times points:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Genomic and immune signatures in terms of progression free survival
Time Frame: 5 years
|
5 years
|
Genomic and immune signatures in terms of overall survival
Time Frame: 5 years
|
5 years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Amit Oza, M.D., Princess Margaret Cancer Centre
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- VENUS
- 17-5411 (Other Identifier: UHN REB)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gynecologic Cancer
-
University of LouisvilleJames Graham Brown Cancer CenterCompleted
-
Shandong UniversityCompletedGynecologic Cancer | Gynecologic DiseaseChina
-
Washington University School of MedicineWashington University Department of Psychological and Brain SciencesTerminatedStage III Gynecologic Cancer | Stage IV Gynecologic CancerUnited States
-
Azienda Socio Sanitaria Territoriale degli Spedali...CompletedGynecologic Cancer | Surgery | Anesthesia | Hysterectomy | Gynecologic DiseaseItaly
-
Peking Union Medical College HospitalNot yet recruitingGynecologic Cancer
-
IRCCS Policlinico S. MatteoNot yet recruiting
-
Fudan UniversityGuangzhou Burning Rock Dx Co., Ltd.Recruiting
-
Fox Chase Cancer CenterCompleted
-
University Hospital, GenevaCompletedGynecologic CancerSwitzerland
-
Fudan UniversityGuangzhou Burning Rock Bioengineering Ltd.Active, not recruiting
Clinical Trials on Tumour tissue collection
-
CCTU- Cancer ThemeCambridge University Hospitals NHS Foundation Trust; University of CambridgeUnknown
-
University Health Network, TorontoRecruiting
-
Achilles Therapeutics UK LimitedRecruiting
-
Jules Bordet InstituteBristol-Myers Squibb; La Fondation contre le cancer, Belgique; Les Amis de l'Institut... and other collaboratorsRecruitingCNS MetastasesBelgium, France, Luxembourg
-
IgenomixRecruitingLeiomyoma, Uterine | Leiomyosarcoma UterusSpain
-
Fondazione Policlinico Universitario Agostino Gemelli...Recruiting
-
British Columbia Cancer AgencyAmerican Society of Clinical Oncology; BC Cancer Foundation; Terry Fox Research... and other collaboratorsRecruitingCancer | Pancreatic CancerCanada
-
Assistance Publique - Hôpitaux de ParisInstitut National de la Santé Et de la Recherche Médicale, France; FONCER contre...RecruitingRenal Cell Carcinoma | Renal Cancer | Renal Cancer MetastaticFrance
-
University Health Network, TorontoRecruiting
-
Medical University of South CarolinaActive, not recruitingHead and Neck CancerUnited States